Cellectar Biosciences CLRB Stock
Cellectar Biosciences Price Chart
Cellectar Biosciences CLRB Financial and Trading Overview
| Cellectar Biosciences stock price | 2.5 USD |
| Previous Close | 2.79 USD |
| Open | 2.73 USD |
| Bid | 1.93 USD x 200 |
| Ask | 3.32 USD x 200 |
| Day's Range | 2.55 - 2.88 USD |
| 52 Week Range | 2.2 - 10.19 USD |
| Volume | 94.72K USD |
| Avg. Volume | 1.04M USD |
| Market Cap | 20.54M USD |
| Beta (5Y Monthly) | 0.535 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.38 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.33 USD |
CLRB Valuation Measures
| Enterprise Value | 15.62M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.6029139 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.870482 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.705 |
Trading Information
Cellectar Biosciences Stock Price History
| Beta (5Y Monthly) | 0.535 |
| 52-Week Change | -73.50% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 10.19 USD |
| 52 Week Low | 2.2 USD |
| 50-Day Moving Average | 2.84 USD |
| 200-Day Moving Average | 3.46 USD |
CLRB Share Statistics
| Avg. Volume (3 month) | 1.04M USD |
| Avg. Daily Volume (10-Days) | 154.02K USD |
| Shares Outstanding | 7.99M |
| Float | 7.82M |
| Short Ratio | 0.09 |
| % Held by Insiders | 2.07% |
| % Held by Institutions | 16.61% |
| Shares Short | 258.2K |
| Short % of Float | 3.23% |
| Short % of Shares Outstanding | 3.23% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -102.96% |
| Return on Equity (ttm) | -290.41% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -22162094 USD |
| Net Income Avi to Common (ttm) | -20840954 USD |
| Diluted EPS (ttm) | -5.38 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 8.35M USD |
| Total Cash Per Share (mrq) | 1.04 USD |
| Total Debt (mrq) | 1.53M USD |
| Total Debt/Equity (mrq) | 32.41 USD |
| Current Ratio (mrq) | 1.901 |
| Book Value Per Share (mrq) | 0.664 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -18580348 USD |
| Levered Free Cash Flow (ttm) | -12783281 USD |
Profile of Cellectar Biosciences
| Country | United States |
| State | NJ |
| City | Florham Park |
| Address | 100 Campus Drive |
| ZIP | 07932 |
| Phone | 608 441 8120 |
| Website | https://www.cellectar.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 11 |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Q&A For Cellectar Biosciences Stock
What is a current CLRB stock price?
Cellectar Biosciences CLRB stock price today per share is 2.5 USD.
How to purchase Cellectar Biosciences stock?
You can buy CLRB shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cellectar Biosciences?
The stock symbol or ticker of Cellectar Biosciences is CLRB.
Which industry does the Cellectar Biosciences company belong to?
The Cellectar Biosciences industry is Biotechnology.
How many shares does Cellectar Biosciences have in circulation?
The max supply of Cellectar Biosciences shares is 7.99M.
What is Cellectar Biosciences Price to Earnings Ratio (PE Ratio)?
Cellectar Biosciences PE Ratio is now.
What was Cellectar Biosciences earnings per share over the trailing 12 months (TTM)?
Cellectar Biosciences EPS is -5.38 USD over the trailing 12 months.
Which sector does the Cellectar Biosciences company belong to?
The Cellectar Biosciences sector is Healthcare.
Cellectar Biosciences CLRB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Composite Total Return
XCMP
US
|
31560.2 USD — |
-2.21
|
— — | 31469.2 USD — | 31924.72 USD — | — - | — — |
|
US Tech Capital Market Composite
RCMP
US
|
146.53 USD — |
-0.75
|
— — | 144.14 USD — | 148.72 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}